Bladder Cancer

Bill, a USC Norris patient, joined the SUNRiSE-1 trial for Inlexzo, avoiding bladder removal and reaching full remission from BCG-unresponsive bladder cancer.

Fran Curtis is a survivor of breast, appendix and skin cancer, but said bladder cancer was the toughest.

The FDA accepted an application for Padcev plus Keytruda for patients with muscle-invasive bladder cancer ineligible for cisplatin-containing chemotherapy.

Loqtorzi improved progression-free and overall survival versus chemotherapy in HER2-expressing advanced urothelial cancer.

Adding Imfinzi to Bacillus Calmette-Guérin therapy improved disease-free survival for patients with high-risk, non-muscle invasive bladder cancer.

Among patients with muscle-invasive bladder cancer, perioperative Imfinzi to chemotherapy doesn’t have a detrimental effect on patient-reported outcomes.

The addition of Tecentriq to BCG therapy did not significantly improve outcomes for patients with non–muscle-invasive bladder versus BCG alone.

When reflecting on the Japanese art of kintsugi, one can find inspiration during a cancer journey, as CURE columnist Chester Freeman explained.

Dr. Patrick J. Hensley explains non-muscle invasive bladder cancer, bladder-preserving treatments, trial eligibility, novel therapies and research priorities for patients.

In September 2025, the FDA approved new treatments for breast, bladder and prostate cancers, plus biosimilars and a subcutaneous immunotherapy option.

Frank Garred, 77, completed Inlexzo treatment for recurrent bladder cancer, describing it as manageable with minimal side effects compared with BCG.

Dr. Patrick J. Hensley shares the treatment landscape of non-muscle-invasive bladder, as well as how individual risk factors can alter treatment options.

Urothelial carcinoma, the most common type of bladder cancer, is explained from diagnosis to treatment.

This issue of CURE highlights personal stories and expert insights, from living with multiple diagnoses to self-advocacy, nutrition and survivorship care.

The FDA has approved Inlexzo for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.

TAR-200 eliminated tumors in 82% of patients in a phase 2 trial for patients with high-risk non-muscle-invasive bladder cancer.

PredicineCARE, a urine-based test, is under FDA review as a companion diagnostic for bladder cancer, building on previous data and biomarker insights.

This guide provides an overview of bladder cancer, from diagnosis to treatment, helping patients understand options, manage side effects, and plan care.

Alpha1H shows benefit in non-muscle invasive bladder cancer, shrinking tumors and boosting the immune system with manageable side effects.

Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.

Clinical trial updates in cancer care include a remote study in small cell lung cancer and new findings in ovarian, solid tumor, and urothelial cancers.

In a phase 3 trial, 72.2% of patients with recurrent low-grade bladder cancer kept complete response at 24 months after Zusduri treatment.

CURE spoke with experts about radical cystectomy, or surgical removal of the bladder, for patients with bladder cancer.

Patients with high-risk bladder cancer reported similar quality of life when treated with sasanlimab plus BCG versus BCG alone, new study data showed.

Treatment with Zusduri had a median duration of response of 3.5 years and event-free survival of two years in low-grade intermediate-risk bladder cancer.